The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

Although infection by SARS-CoV-2, the causative agent of coronavirus pneumonia disease (COVID-19), is spreading rapidly worldwide, no drug has been shown to be sufficiently effective for treating COVID-19. We previously found that nafamostat mesylate, an existing drug used for disseminated intravascular coagulation (DIC), effectively blocked Middle East respiratory syndrome coronavirus (MERS-CoV) S protein-mediated cell fusion by targeting transmembrane serine protease 2 (TMPRSS2), and inhibited MERS-CoV infection of human lung epithelium-derived Calu-3 cells. Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active. Furthermore, nafamostat mesylate blocked SARS-CoV-2 infection of Calu-3 cells with an effective concentration (EC)50 around 10 nM, which is below its average blood concentration after intravenous administration through continuous infusion. On the other hand, a significantly higher dose (EC50 around 30 μM) was required for VeroE6/TMPRSS2 cells, where the TMPRSS2-independent but cathepsin-dependent endosomal infection pathway likely predominates. Together, our study shows that nafamostat mesylate potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and also inhibits SARS-CoV-2 infection in vitro in a cell-type-dependent manner. These findings, together with accumulated clinical data regarding nafamostat’s safety, make it a likely candidate drug to treat COVID-19.

[1]  Fang Li,et al.  Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[2]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[3]  M. Müller,et al.  Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 , 2020, Antimicrobial Agents and Chemotherapy.

[4]  H. Ogawa,et al.  Potential of heparin and nafamostat combination therapy for COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[5]  Qiang Sun,et al.  Systemic analysis of tissue cells potentially vulnerable to SARS-CoV-2 infection by the protein-proofed single-cell RNA profiling of ACE2, TMPRSS2 and Furin proteases , 2020, bioRxiv.

[6]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[7]  Jenny Y. Zhang,et al.  Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19) , 2020, Journal of Translational Medicine.

[8]  B. Russ,et al.  Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human Cells , 2020 .

[9]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.

[10]  M. Shimojima,et al.  The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 , 2020, bioRxiv.

[11]  Fumihiro Kato,et al.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.

[12]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[13]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[14]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[15]  J. Inoue,et al.  TRAF6 maintains mammary stem cells and promotes pregnancy-induced mammary epithelial cell expansion , 2019, Communications Biology.

[16]  Yukiko Shimizu,et al.  TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection , 2019, Journal of Virology.

[17]  Yoshimasa Tanaka,et al.  TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections , 2017, Biochimie.

[18]  Makoto Takeda,et al.  Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay , 2016, Antimicrobial Agents and Chemotherapy.

[19]  M. Ramakrishnan Determination of 50% endpoint titer using a simple formula. , 2016, World journal of virology.

[20]  Shujun Liu,et al.  Co-Expression of Foreign Proteins Tethered to HIV-1 Envelope Glycoprotein on the Cell Surface by Introducing an Intervening Second Membrane-Spanning Domain , 2014, PloS one.

[21]  L. van der Hoek,et al.  Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry , 2012, Journal of Virology.

[22]  S. Kao,et al.  Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. , 2006, The Journal of allergy and clinical immunology.

[23]  T. Kitamura,et al.  Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. , 2003, Experimental hematology.